Keywords: Adverse effects, biologics, psoriasis, therapy. Open label trial of alefacept in palmoplantar pustular psoriasis. Keywords: psoriasis, adalimumab, tumor necrosis factor alpha. Duvic M. Generalized pustular psoriasis following withdrawal of efalizumab. We report here the treatment of an adolescent girl who responded to adalimumab after failing to respond to a combination of methotrexate, cyclosporin and isotretinoin, and having had a pustular reaction that followed the use of etanercept, but might have been triggered by an infection. Key words: Pustular psoriasis, adalimumab therapy, biologic therapy of psoriasis.
However, long-term treatment in patients with moderate to severe psoriasis is limited by the potential for toxic effects on organs, such as renal, hepatic or bone marrow, in addition to teratogenicity and malignancies that are associated with the traditional systemic therapies. Four biologic therapies (adalimumab, efalizumab, etanercept and infliximab) which had been thoroughly revised, are now licensed for the treatment of moderate-to-severe psoriasis. Biologics Childhood Pediatric psoriasis Systemic treatments. Acitretin is a second-generation aromatic retinoid suitable for children with generalized flares and pustular psoriasis as intermittent rescue therapy and in case of pustular, erythrodermic or severe plaque psoriasis of older children as long-term therapy 30. Adalimumab is a monoclonal antibody against TNF. Biological therapies of proven benefit in severe psoriasis include etanercept, adalimumab and infliximab, which target tumour necrosis factor. Key words: adalimumab, efalizumab, etanercept, infliximab, ustekinumab.
Key Words: biologic agents, childhood, pediatric psoriasis. There are two case reports in the literature detailing the successful use of adalimumab for recalcitrant pustular psoriasis in adolescent girls after failure of other systemic and biologic agents. Keywords: Biologics; proteins; autoimmune diseases. In a trial, patients with psoriatic arthritis received adalimumab every other week for 24 week14. Successful treatment for severe psoriasis and generalised pustular psoriasis has been reported with basiliximab, an interleukin-2 receptor (IL-2R; CD25) chimeric monoclonal antibody 18, 19. However, the patient refused to receive treatment with a biological agent.
Biologic Systemic Therapy For Moderate-to-severe Psoriasis: A Review